Safety and efficacy of potentised forms of cisplatin and docetaxel
Phase 1
- Conditions
- Health Condition 1: C00-D49- Neoplasms
- Registration Number
- CTRI/2020/05/025045
- Lead Sponsor
- Central Council for Research in Homoeopathy
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1 Pre-diagnosed cases of cancer advised to undergo/undergoing chemotherapy with either cisplatin and/or Docetaxel.
2 Any age group 18 years or above; willing to give written informed consent for participation.
Exclusion Criteria
Patients having chemotherapy with drugs other than cisplatin and docetaxel.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in CTCAE grading and Naranjo ADR score of various components of ADR, every two weeks, physically or telephonically, or as the case may be depending on the next chemotherapy session.Timepoint: Decline in CTCAE grading and Naranjo ADR score of various components of ADR, every two weeks, physically or telephonically, or as the case may be depending on the next chemotherapy session.
- Secondary Outcome Measures
Name Time Method Adherence to chemotherapy regimen, as prescribed by consulting oncologist for at least six months, or for the entire duration of chemotherapy as planned, whichever is earlier.Timepoint: Completion of chemotherapy regimen, as prescribed by consulting oncologist for at least six months, or for the entire duration of chemotherapy as planned, whichever is earlier.